Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers

NCT02252211 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Malignant Solid Tumor
Metastatic EphA2 Positive Cancer

Interventions

DRUG: DS-8895a 1 mg/kg
DRUG: DS-8895a 3 mg/kg
DRUG: DS-8895a 10 mg/kg

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]